Bioidentical hormones vs standard HRT: what is the difference?

Short answer

• “Bioidentical hormones” means hormones whose molecular structure is identical to the hormones your body makes (examples: 17β‑estradiol, micronized progesterone). They can be either FDA‑approved commercial products or custom‑made (compounded) preparations.
• “Standard” or “conventional” HRT usually refers to the commonly prescribed pharmaceutical hormone preparations, which may be bioidentical (estradiol, micronized progesterone) or non‑bioidentical/synthetic (conjugated equine estrogens, synthetic progestins like medroxyprogesterone acetate). The main differences are the exact hormone molecules used, how they are produced/regarded by regulators, and the evidence base about safety and quality.

Key differences (concise)

• Molecule: Bioidentical = chemically identical to human hormones (e.g., 17β‑estradiol, progesterone). Non‑bioidentical (“synthetic”) HRT uses different molecules (e.g., conjugated equine estrogens like Premarin, or progestins like medroxyprogesterone/Provera).
• Source and formulation: FDA‑approved bioidentical products are manufactured with quality controls (examples below). “Compounded bioidentical hormones” are mixed individually by compounding pharmacies to custom strengths/combination and are not individually FDA‑approved.
• Regulation and quality: FDA‑approved pharmaceuticals (Estrace, Climara, Vivelle‑Dot, Prometrium, etc.) have standardized dosing, potency testing, and labeled safety information. Compounded products may vary in potency/consistency and have less standardized oversight—use accredited compounding pharmacies if choosing this route.
• Evidence and safety: There’s no convincing evidence that compounded bioidentical hormones are inherently safer or more effective than FDA‑approved HRT. Risks (blood clots, stroke, breast cancer risk, endometrial hyperplasia if estrogen is unopposed) generally relate to hormonal exposure, route, dose, and individual risk factors. Some formulations/routes (e.g., transdermal estradiol, vaginal low‑dose estrogen, micronized progesterone) may have different risk profiles.

Clinical points to know

• Routes matter: oral vs transdermal vs vaginal. Transdermal estradiol may have lower effect on clotting factors and possibly lower VTE risk than some oral estrogens.
• Progestogen choice matters: micronized progesterone (Prometrium) behaves differently than synthetic progestins (MPA/Provera) and some data suggest differences in side‑effect and possibly cardiovascular/breast risks, but evidence is evolving.
• Testing: routine saliva “hormone tests” are not recommended for dosing menopausal HRT; blood levels don’t reliably reflect tissue effects. Dosing is usually symptom‑directed and individualized, with monitoring for side effects and routine screening as appropriate (mammography, blood pressure, etc.).
• Vaginal/local estrogen: low‑dose local products (Vagifem, Estring, local estradiol creams) are effective for urogenital symptoms with minimal systemic exposure for most women.

Examples of commonly prescribed, FDA‑approved products (for discussion with your clinician)

• Estradiol (oral): Estrace — FDA‑approved estradiol pill.
• Estradiol patches: Climara, Vivelle‑Dot — steady transdermal delivery.
• Conjugated estrogens: Premarin — older, equine estrogen product used historically.
• Combined estrogen+progestin (historical): Prempro — conjugated estrogen + medroxyprogesterone acetate (used in the WHI study).
• Micronized progesterone: Prometrium — bioidentical progesterone in an FDA‑approved formulation.
• Vaginal/local: Vagifem (vaginal tablets), Estring (vaginal ring) — low‑dose local estrogen for vaginal dryness/UTI symptoms.
• Testosterone products (off‑label in many women): AndroGel, Testim — used in some women for low libido but require specialist oversight.

Where to look for reliable guidance and services

• North American Menopause Society (NAMS) — evidence‑based guidelines about menopause and HRT.
• Major centers like Mayo Clinic or Cleveland Clinic patient resources — trustworthy summaries.
• If considering compounded BHRT, use a compounding pharmacy with recognized accreditation (e.g., ACHC or Pharmacy Compounding Accreditation Board) and a clinician experienced in menopause care.

Bottom line / Practical recommendation

• Talk with a clinician who knows menopause management (primary care, OB‑GYN, or menopause specialist). Discuss your symptoms, personal and family risk factors (VTE, cardiovascular disease, breast cancer), and treatment goals.
• Prefer FDA‑approved formulations when suitable (they have known dosing, quality, and safety data). If you still consider compounded bioidentical hormones, use an accredited compounding pharmacy and close medical supervision.
• Don’t assume “bioidentical” = safer or “natural” = risk‑free; individualize the choice by symptoms, risks, and preferences.

If you want, tell me: your main symptoms, medical history (smoking, clot history, breast cancer, etc.), and whether you prefer pills, patches or creams — I can explain which specific options might be best for you and why.